ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules a cross the blood-brain barrier - ABL...
GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia
Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ruxolitinib Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and...
Report: RSV-associated Hospitalisation Costs in Singapore Estimated at SGD 9,430 per Patient; Poses Financial Strain on At-risk Older Adults
New findings from a recent white paper highlight the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV) on at-risk older adults aged 60 years or over in select high-income APEC countries and regions, including Australia, Hong...
Report: RSV-associated Hospitalisation Costs in Singapore Estimated at SGD 9,430 per Patient; Poses Financial Strain on At-risk Older Adults
New findings from a recent white paper highlight the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV) on at-risk older adults aged 60 years or over in select high-income APEC countries and regions, including Australia, Hong...
Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes
People who have had shingles are at a 59% higher risk for heart attack and at a 35% higher risk for stroke compared to those who have not had shingles. Adults aged 50 years or over are at high risk for shingles due to age-related decline in immunity...
A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others
TOKYO, Jan. 30, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight projects for the development of new diagnostics and drugs for...
GSK Leads Global Forum in Bangkok to Address Respiratory Health Challenges
GSK hosted the third annual RespiVerse Meeting on December 13 and 14 in Bangkok, Thailand. The event brought together renowned international speakers and healthcare professionals from 17 countries to address pressing global challenges in respiratory...
Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)
PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics,...